Matthew Miller

Mr. Matthew Miller

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sachiko KoyamaSachiko Koyama
Sachiko Koyama
JEJumar Etkins
Jumar Etkins
JJJoshua Jun
Joshua Jun
MMMatthew Miller
Matthew Miller
GSGerald Chun-To So
Gerald Chun-To So
MEMichael Eadon
Michael Eadon
Cannabidiol (CBD) is one of the major phytochemical constituents of cannabis, Cannabis sativa, widely recognized for its therapeutic potential. While cannabis has been utilized for medicinal purposes since ancient times, its psychoactive and addictive properties led to its prohibition in 1937, with only the medical use being reauthorized in 1998. Unlike tetrahydrocannabinol (THC), CBD lacks psychoactive and addictive properties, yet the name that suggests its association with cannabis has significantly contributed to its public visibility. CBD exhibits diverse pharmacological properties, most notably anti-inflammatory effects. Additionally, it interacts with key drug-metabolizing enzyme families, including cytochrome P450 (CYP) and uridine 5′-diphospho-glucuronosyltransferase (UGT), which mediate phase I and phase II metabolism, respectively. By binding to these enzymes, CBD can inhibit the metabolism of co-administered drugs, which can potentially enhance their toxicity or therapeutic effects. Mild to moderate adverse events associated with CBD use have been reported. Advances in chemical formulation techniques have recently enabled strategies to minimize these effects. This review provides an overview of CBD, covering its historical background, recent clinical trials, adverse event profiles, and interactions with molecular targets such as receptors, channels, and enzymes. We particularly emphasize the mechanisms underlying its anti-inflammatory effects and interaction with drugs relevant to organ transplantation. Finally, we explore recent progress in the chemical formulation of CBD in order to enhance its bioavailability, which will enable decreasing the dose to use and increase its safety and efficacy.

26 December 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
JEJumar Etkins
Jumar Etkins
GSGerald Chun-To So
Gerald Chun-To So
JLJessica Bo Li Lu
Jessica Bo Li Lu
Sachiko KoyamaSachiko Koyama
Sachiko Koyama
DGDebora L. Gisch
Debora L. Gisch
MEMichael Eadon
Michael Eadon
Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype‐specific adverse events and pharmacokinetic profiles of cannabidiol, 7‐OH cannabidiol (an active metabolite), and 7‐COOH cannabidiol. We completed a secondary analysis of an open‐label, fixed‐sequence, single‐center study of cannabidiol in 33 healthy subjects. Patients first received a single dose of cannabidiol 5 mg/kg orally with serial plasma concentrations measured. Later, patients were titrated to 5 mg/kg twice daily for 14 days to reach steady state with serial plasma concentrations measured. CYP3A, CYP2C9, and CYP2C19 genotypes were assessed. Pharmacokinetic parameters were calculated by noncompartmental analysis. Diarrhea was observed more frequently in individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism (39%) compared to individuals with other genotypes (7%, p = 0.0463). Individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism had increased 7‐OH cannabidiol and 7‐COOH cannabidiol exposure at steady state. Cannabidiol parent drug exposure varied by CYP2C19 metabolizer status, with lower cannabidiol exposure and parent to metabolite ratios in intermediate metabolizers after single dose ( p = 0.014) and at steady state ( p = 0.0033). Similar CYP2C19 genotype‐specific exposure was observed in an external validation cohort. Minor differences in exposure of cannabidiol and its metabolites were observed between CYP3A5 and CYP2C9 genotype groups. Significant changes in pharmacokinetics were observed between CYP2C9, CYP2C19, and CYP3A5 genotype groups. Future studies should assess whether pharmacogenomics can predict intestinal concentrations of CBD, its metabolites, and diarrhea.